Diagnosis changes lives

Patients and clinicians are faced with hard choices as to how best to treat brain tumours, as well as how to address the inevitable side effects of the disease and of the various treatment options. Conventional radiation therapies affect areas of the brain unaffected by cancer as well as the diseased tissue; a large proportion of brain cancer survivors suffer cognitive loss due to the treatments that saved their lives. 40% of patients with brain tumours – and 90% of those with tumours due to gliomas – will also experience epileptic seizures.

MEG benefits oncology treatment planning

Magnetoencephalography (MEG) needs to be at the heart of the oncology diagnostic and treatment planning. As well as bringing unparalleled accuracy to pre-surgical functional mapping, MEG allows oncologists to create optimal treatment plans that identify and mitigate cognitive decline. Plus MEG allows for the most accurate localisation of epileptic areas in the brain, reducing the impact of this serious side effect in many patients. A multi-modal approach to oncology treatment planning including MEG leads to improved treatment outcomes and better quality of life for brain cancer survivors.

MEGSCAN is for investigational use only. It is not available for clinical use until regulatory approvals have been granted.

The treatment pipeline with MEG

Before treatment begins

Patient has MEG scan to understand extent and functional areas affected by the tumour. Patient is assessed during scan to understand impact on areas of cognition: memory, mood, functional ability. Epileptic activity is also assessed with analysis of interictal activity.

Enhancing effectiveness of treatment options

MEG is used for pre-surgical functional mapping – to clearly flag eloquent areas before surgery takes place to remove the tumour. MEG can aid in choice of treatment plans – by clearly identifying the extent of the tumour, targeted local treatment options such as proton beam therapy can be optimized to minimize the negative impact on the patient.

During and post treatment assessments

MEGSCAN will determine the impact of treatment options especially in terms of cognitive decline. This aids the oncologist in their decisions with regards to ongoing treatment planning. Understanding the impact of their cancer treatment and recovery aids the patient in making adjustments to their living accordingly.

Why is MEGSCAN so effective?

  • MEGSCAN offers a direct measure of brain function. This is unlike MRI and fMRI which are secondary measures of function
  • High temporal resolution. Events with millisecond duration/frequency can be resolved, unlike fMRI, PET and SPECT, which have much longer time scales.
  • High spatial resolution. Sources can be localized with millimetre accuracy. This includes those who have had past brain surgery, where EEG may be severely distorted.
  • MEGSCAN’s HyQUID sensors pick up a wider dynamic range of signal than ever before. Located at 320 independent positions all  over the scalp, the sensors give more comprehensive brain coverage than any other MEG system currently on the market.
  • MEGSCAN is completely non-invasive, safe and silent.